A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

Child and Adolescent Psychiatry and Mental Health

Volumn 3, Issue , 2009, Pages

  Wigal, Sharon B ^a   Kollins, Scott H ^b   Childress, Ann C ^c   Squires, Liza ^d   Brams, Matthew ^e   Childress, Ann ^e   Lerner, Marc A ^e   Moon, Eliot ^e   Turnbow, John M ^e   Vince, Bradley ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Center for Psychiatry and Behavioral Medicine   (United States)

^d SHIRE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

LISDEXAMFETAMINE; PLACEBO;

ABDOMINAL PAIN; AMNESIA; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER RATING SCALE IV; BLUNTED AFFECT; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; LABORATORY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OPTIMAL DRUG DOSE; PERMANENT PRODUCT MEASURE OF PERFORMANCE; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; SWANSON KOTKIN AGLER M FLYNN AND PELHAM SCALE; SYSTOLIC BLOOD PRESSURE; TARDIVE DYSKINESIA; VITAL SIGN; VOMITING; WEIGHT REDUCTION;

EID: 67650225546     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-3-17     Document Type: Article

References (34)

1. Pliszka SR Crismon ML Hughes CW Conners CK Emslie GJ Jensen PS McCracken JT Swanson JM Lopez M the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 2006, 45:642-657 10.1097/ 01.chi.0000215326.51175.eb 16721314
2. Dulcan M the Work Group on Quality Issues Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 1997, 36(10 suppl):85S-121S 9334567
3. Stein MA Baren M Welcome progress in the diagnosis and treatment of ADHD in adolescence Contemp Pediatr 2003, 20:83-110
4. Solanto MV Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: A review and integration Behav Brain Res 1998, 94:127-152 10.1016/ S0166-4328(97)00175-7 9708845
5. Weiss G Minde K Douglas V Werry J Sykes D Comparison of the effects of chlorpromazine, dextroamphetamine and methylphenidate on the behaviour and intellectual functioning of hyperactive children Can Med Assoc J 1971, 104:20-25 1930823 5540117
6. Pliszka S Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 2007, 46:894-921 10.1097/ chi.0b013e318054e724 17581453
7. Arnold LE Methylphenidate vs. amphetamine: Comparative review J Atten Disord 2000, 3(4):200-211 10.1177/108705470000300403
8. Pelham WE Jr Greenslade KE Vodde-Hamilton M Murphy DA Greenstein JJ Gnagy EM Guthrie KJ Hoover MD Dahl RE Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline Pediatrics 1990, 86:226-237 2196522
9. Faraone SV Lisdexamfetamine dimesylate: The first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder Expert Opin Pharmacother 2008, 9:1565-1574 10.1517/14656566.9.9.1565 18518785
10. Biederman J Krishnan S Zhang Y McGough JJ Findling RL Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study Clin Ther 2007, 29:450-463 10.1016/S0149-2918(07)80083-X 17577466
11. Weisler R Young J Mattingly G Gao J Squires L Adler L Long-term safety and efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder Poster presented at: The US Psychiatric and Mental Health Congress; October 30-November 2, 2008; San Diego, CA. Poster 206
12. Krishnan S Zhang Y Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: A single-dose, crossover pharmacokinetic study J Clin Pharmacol 2008, 48:293-302 10.1177/0091270007310381 18285619
13. Biederman J Boellner SW Childress A Lopez FA Krishnan S Zhang Y Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study Biol Psychiatry 2007, 62:970-976 10.1016/ j.biopsych.2007.04.015 17631866
14. Wigal SB Gupta S Guinta D Swanson JM Reliability and validity of the SKAMP rating scale in a laboratory school setting Psychopharmacol Bull 1998, 34:47-53 9564198
15. DuPaul GJ Power TJ Anastopoulos AD Reid R ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation New York, NY; Guilford Press 1998
16. Conners CK Conners' Rating Scales - Revised Technical Manual North Tonawanda, NY: Multi-Health Systems Inc 2001
17. American Psychiatric Association Substance-related disorders Diagnostic and Statistical Manual of Mental Disorders DSM-IV Washington, DC: American Psychiatric Association 4 1994
18. Kaufman AS Kaufman NL KBIT-2: Kaufman Brief Intelligence Test Upper Saddle River, NJ: Pearson Education, Inc. Second 2004
19. Wigal SB Wigal TL The laboratory school protocol: Its origin, use, and new applications J Atten Disord 2006, 10:92-111 10.1177/1087054705286049 16840597
20. Guy W Clinical global impressions ECDEU Assessment Manual for Psychopharmacology Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch 1976:218-222
21. Adderall XR [package insert] Wayne, PA: Shire US Inc 2007
22. Concerta [package insert] Titusville, NJ: McNeil Pediatrics 2008
23. Focalin XR [package insert] East Hanover, NJ: Novartis Pharmaceuticals Corporation 2008
24. Krishnan SM Stark JG Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers Curr Med Res Opin 2008, 24:33-40 18021493
25. Vyvanse [package insert] Wayne, PA: Shire US Inc. 2008
26. A Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Treament, 3-Period, Crossover Study with One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR®, or Placebo in Children Aged 6 to 12 years with Attention-Deficit Hyperactivity Disorder (ADHD) New River Pharmaceuticals Inc. Protocol NRP104.201 Data on File http://clinicaltrials.gov/ct2/show/study/NCT00557011
27. Wigal S Swanson JM Feifel D Sangal RB Elia J Casat CD Zeldis JB Conners CK A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d, l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 2004, 43:1406-1414 10.1097/01.chi.0000138351.98604.92 15502600
28. Biederman J Lopez FA Boellner SW Chandler MC A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder Pediatrics 2002, 110:258-266 10.1542/peds.110.2.258 12165576
29. Wolraich ML Greenhill LL Pelham W Swanson J Wilens T Palumbo D Atkins M McBurnett K Bukstein O August G Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder Pediatrics 2001, 108:883-892 10.1542/ peds.108.4.883 11581440
30. McGough JJ Wigal SB Abikoff H Turnbow JM Posner K Moon E A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD J Atten Disord 2006, 9:476-485 10.1177/1087054705284089 16481664
31. Swanson JM Wigal S Greenhill LL Browne R Waslik B Lerner M Williams L Flynn D Agler D Crowley K Fineberg E Baren M Cantwell DP Analog classroom assessment of Adderall® in children with ADHD J Am Acad Child Adolesc Psychiatry 1998, 37:519-526 10.1097/ 00004583-199805000-00014 9585654
32. McCracken JT Biederman J Greenhill LL Swanson JM McGough JJ Spencer TJ Posner K Wigal S Pataki C Zhang Y Tulloch S Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD J Am Acad Child Adolesc Psychiatry 2003, 42:673-683 10.1097/01.CHI.0000046863.56865.FE 12921475
33. Pierce D Dixon CM Wigal SB McGough JJ Pharmacokinetics of methylphenidate transdermal system (MTS): Results from a laboratory classroom study J Child Adolesc Psychopharmacol 2008, 18:355-364 10.1089/ cap.2007.0148 18759645
34. Spencer TJ Biederman J Mick E Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology J Pediatr Psychol 2007, 32:631-642 10.1093/jpepsy/jsm005 17556405